Genfit(GNFTF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GNFTF Genfit

Trading 03-13 11:54:00 EDT Delay

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"GNFTF","market":"US","secType":"STK","nameCN":"Genfit","latestPrice":3.54,"timestamp":1741881240000,"preClose":3.54,"halted":0,"volume":0,"delay":15,"floatShares":41846888,"shares":49758671,"eps":-0.642605,"marketStatus":"Trading","change":0,"latestTime":"03-13 11:54:00 EDT Delay","open":3.54,"high":3.54,"low":3.54,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.642605,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1741896000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":3.54,"volumeRatio":0},"requestUrl":"/m/hq/s/GNFTF","defaultTab":"news","newsList":[{"id":"2518789688","title":"GENFIT Secures Bondholder Approval for 2025 OCEANEs Amendments","url":"https://stock-news.laohu8.com/highlight/detail?id=2518789688","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518789688?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 05:34","pubTimestamp":1741642497,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Genfit SA ( ($GNFT) ). On March 10, 2025, GENFIT announced the approval of amendments to the terms and conditio...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfit-secures-bondholder-approval-for-2025-oceanes-amendments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfit-secures-bondholder-approval-for-2025-oceanes-amendments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF","BK4139"],"gpt_icon":0},{"id":"2518778574","title":"Press Release: Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs","url":"https://stock-news.laohu8.com/highlight/detail?id=2518778574","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518778574?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 05:10","pubTimestamp":1741641000,"startTime":"0","endTime":"0","summary":"Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs. -- Closing of Royalty Financing and receipt of first EUR130 million. -- Upon closing of the Royalty Financing, GENFIT will implement the. Repurchase of the 2025 OCEANEs and pay the Consent Fee. The terms and conditions of the 2025 OCEANEs contained a negative pledge clause which limited the ability of the Company to grant security interests to its creditors upon its present or future assets or revenues. The closing of the royalty financing with HCRx , which was signed and announced by GENFIT on January 30, 2025, was subject to approval of 2025 OCEANEs bondholders of an amendment to this negative pledge clause, allowing for the grant of the security interest contemplated in the Royalty Financing documentation, and other customary closing conditions.The result of the vote resolution by resolution is available on the website of the Company .The Company also undertook, s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","USA","GNFT","CCA","PBC","GNFTF","BK4022","BK4139","BK4232"],"gpt_icon":0},{"id":"2516598460","title":"Analysts’ Top Healthcare Picks: Genfit (GNFTF), Ventyx Biosciences (VTYX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516598460","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516598460?lang=en_us&edition=full_marsco","pubTime":"2025-03-02 09:40","pubTimestamp":1740879606,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Genfit (GNFTF – Research Report) and Ventyx Bioscien...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-genfit-gnftf-ventyx-biosciences-vtyx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-genfit-gnftf-ventyx-biosciences-vtyx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","VTYX","GNFTF","BK4007","HCSG","BK4139"],"gpt_icon":0},{"id":"2514835841","title":"GENFIT Announces Revenues and Cash Position as of December 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2514835841","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514835841?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 05:10","pubTimestamp":1740690600,"startTime":"0","endTime":"0","summary":"Cash and cash equivalents totaled 81.8 million as of December 31, 2024. Revenues amounted to 67.0 million as of December 31, 2024 including the 48.7 million milestone upon first sale of Ipsen’s Iqirvo  in the U.S. for the treatment of Primary Biliary Cholangitis . Lille , Cambridge , Zurich , February 27, 2025 - GENFIT , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of December 31, 2024 and revenues for 2024. As of December 31, 2024, the Company’s cash and cash equivalents amounted to 81.8 million compared with 77.8 million as of December 31, 2023 and 96.0 million as of September 30, 2024.Of the 67.0 million, 48.7 million was attributable to a milestone payment invoiced to Ipsen in June 2024 and 2.7 million was attributable to royalty revenue from U.S. sales of Iqirvo/elafibranor which commenced mid-June in application of the Ipsen Agreement signed in December 2021. 15.3 milli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genfit-announces-revenues-cash-position-211000393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GNFT","GNFTF"],"gpt_icon":0},{"id":"2513785685","title":"Kepler Capital  Sticks to Its Buy Rating for Genfit (GNFTF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2513785685","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513785685?lang=en_us&edition=full_marsco","pubTime":"2025-02-23 09:37","pubTimestamp":1740274642,"startTime":"0","endTime":"0","summary":"In a report released on February 21, Justine Telliez from Kepler Capital maintained a Buy rating on Genfit (GNFTF – Research Report), with a price ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/kepler-capital-sticks-to-its-buy-rating-for-genfit-gnftf-5?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/kepler-capital-sticks-to-its-buy-rating-for-genfit-gnftf-5?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF"],"gpt_icon":0},{"id":"2513878298","title":"GENFIT Advances 2025 OCEANEs Repurchase with Key Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2513878298","media":"TIPRANKS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513878298?lang=en_us&edition=full_marsco","pubTime":"2025-02-21 21:27","pubTimestamp":1740144463,"startTime":"0","endTime":"0","summary":"An update from Genfit SA ( ($GNFT) ) is now available. On February 21, 2025, GENFIT announced the preliminary results of its repurchase offer for 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfit-advances-2025-oceanes-repurchase-with-key-agreements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfit-advances-2025-oceanes-repurchase-with-key-agreements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF","BK4139"],"gpt_icon":0},{"id":"2513305892","title":"Press Release: GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2513305892","media":"Dow Jones","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513305892?lang=en_us&edition=full_marsco","pubTime":"2025-02-21 15:30","pubTimestamp":1740123000,"startTime":"0","endTime":"0","summary":"GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting. -- Put Option Agreements signed to date with 2025 OCEANEs holders. -- 2025 OCEANEs holders' general meeting convened for March 10, 2025. Lille , Cambridge , Zurich , February 21, 2025 - GENFIT , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that it has signed Put Option Agreements with 2025 OCEANEs holders and the convening of the general meeting of the 2025 OCEANEs holders for March 10, 2025.As announced on February 10, 2025 and February 14, 2025, GENFIT has proposed to all of the 2025 OCEANEs holders to enter into a Put Option Agreement, pursuant to which GENFIT will unconditionally and irrevocably undertake to repurchase the 2025 OCEANEs of such holder, subject to approval by the general meeting of the 2025 OCEANEs holders of the amendment of t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4139","CCA","PBC","GNFTF","BK4232","GNFT","R","USA"],"gpt_icon":0},{"id":"2511610727","title":"GENFIT Amends Terms of 2025 OCEANEs Proposal Amid Royalty Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2511610727","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511610727?lang=en_us&edition=full_marsco","pubTime":"2025-02-15 05:27","pubTimestamp":1739568453,"startTime":"0","endTime":"0","summary":"Genfit SA ( ($GNFT) ) has shared an update. On February 14, 2025, GENFIT announced amendments to the terms of its dual proposal to the 2025 OCEANEs...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfit-amends-terms-of-2025-oceanes-proposal-amid-royalty-financing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfit-amends-terms-of-2025-oceanes-proposal-amid-royalty-financing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF","BK4139"],"gpt_icon":0},{"id":"2511683281","title":"Genfit (GNFTF) Gets a Buy from Kepler Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2511683281","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511683281?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 09:38","pubTimestamp":1739497109,"startTime":"0","endTime":"0","summary":"Kepler Capital analyst Justine Telliez maintained a Buy rating on Genfit (GNFTF – Research Report) on February 12 and set a price target of €8.40. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/genfit-gnftf-gets-a-buy-from-kepler-capital-5?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/genfit-gnftf-gets-a-buy-from-kepler-capital-5?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GNFTF"],"gpt_icon":0},{"id":"2510465858","title":"GENFIT Finalizes 2025 Bond Repurchase Terms Amidst Royalty Financing Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2510465858","media":"TIPRANKS","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510465858?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 19:28","pubTimestamp":1739186902,"startTime":"0","endTime":"0","summary":"Genfit SA ( ($GNFT) ) has issued an announcement. On February 10, 2025, GENFIT announced the final terms for a dual proposal to its 2025 OCEANEs bo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfit-finalizes-2025-bond-repurchase-terms-amidst-royalty-financing-deal?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfit-finalizes-2025-bond-repurchase-terms-amidst-royalty-financing-deal?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","US3Y.BOND","US6M.BOND","US12M.BOND","US2Y.BOND","US10Y.BOND","GNFTF","US30Y.BOND","US5Y.BOND","US7Y.BOND"],"gpt_icon":0},{"id":"2510886345","title":"GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2510886345","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510886345?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 14:30","pubTimestamp":1739169000,"startTime":"0","endTime":"0","summary":"In conjunction with the royalty financing deal with HealthCare Royalty  announced on January 30, 2025, GENFIT will request the consent of the holders of 2025 OCEANEs and proposes:. to repurchase the 2025 OCEANEs at EUR 32.00 per bond from interested bondholders, or alternatively. to pay a consent fee of EUR 0.60 per bond still outstanding after the upcoming bondholder meeting and cancellation of the repurchased 2025 OCEANEs. Both proposals are subject to approval of the royalty financing by the 2025 OCEANEs bondholders at the upcoming bondholders meeting and closing of the royalty financing. Lille , Cambridge , Zurich , February 10, 2025 - GENFIT , a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the final terms of the 2025 OCEANEs repurchase proposal and the consent fee that would be paid to the holders of 2025 OCEANEs still outstanding after cancellation of repurchased 2025 OCEANEs.Concurrently wit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genfit-announces-final-terms-dual-063000451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GNFTF","USA","CCA","BK4139","GNFT","PBC"],"gpt_icon":0},{"id":"2510509568","title":"Kepler Capital  Reaffirms Their Buy Rating on Genfit (GNFTF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510509568","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510509568?lang=en_us&edition=full_marsco","pubTime":"2025-02-09 09:46","pubTimestamp":1739065599,"startTime":"0","endTime":"0","summary":"Kepler Capital analyst Justine Telliez maintained a Buy rating on Genfit (GNFTF – Research Report) on February 7 and set a price target of €8.40. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/kepler-capital-reaffirms-their-buy-rating-on-genfit-gnftf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/kepler-capital-reaffirms-their-buy-rating-on-genfit-gnftf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF"],"gpt_icon":0},{"id":"2509481037","title":"Genfit Price Target Maintained With a $13.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2509481037","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509481037?lang=en_us&edition=full_marsco","pubTime":"2025-02-07 20:45","pubTimestamp":1738932300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GNFT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 07, 2025 07:45 ET (12:45 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNFTF","GNFT"],"gpt_icon":0},{"id":"2509371431","title":"Genfit SA’s Promising Clinical Milestones and Financial Stability Underpin Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2509371431","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509371431?lang=en_us&edition=full_marsco","pubTime":"2025-02-07 19:37","pubTimestamp":1738928253,"startTime":"0","endTime":"0","summary":"Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Genfit SA (GNFT – Research Report), with a price target of $13.00. Ed Arce’s rating i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/genfit-sas-promising-clinical-milestones-and-financial-stability-underpin-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/genfit-sas-promising-clinical-milestones-and-financial-stability-underpin-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF"],"gpt_icon":0},{"id":"2509784847","title":"GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2509784847","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509784847?lang=en_us&edition=full_marsco","pubTime":"2025-02-07 05:10","pubTimestamp":1738876200,"startTime":"0","endTime":"0","summary":"2 new ACLF clinical trials expected to initiate in 1Q25. 3 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT Phase 2 trial. Data of on-going Phase 1b also expected by year-end 2025 for GNS561/trametinib in KRAS-mutated cholangiocarcinoma, to support dose selection for Phase 2. Lille , Cambridge , Zurich , February 6, 2025-GENFIT ,a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today outlines the design of new clinical trials within its Acute on-Chronic Liver Failure  pipeline, with several clinical data readouts by end of 2025.This integrated approach ensures a comprehensive foundation to advance our ACLF pipeline. Notably, it has provided the rationale for including a subset of patients with AD at a high-risk of progressing to ACLF in our target population for the new trials. Broadening inclusion criteria to cover the ACLF continuum creates opportunities to add","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genfit-outlines-anticipated-clinical-trial-211000282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GNFT","USA","BK4081","PBC","BK4139","GNFTF","CCA","HE"],"gpt_icon":0},{"id":"2508391291","title":"Kepler Capital  Sticks to Its Buy Rating for Genfit (GNFTF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2508391291","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508391291?lang=en_us&edition=full_marsco","pubTime":"2025-02-01 09:36","pubTimestamp":1738373819,"startTime":"0","endTime":"0","summary":"Kepler Capital analyst Justine Telliez maintained a Buy rating on Genfit (GNFTF – Research Report) on January 30 and set a price target of €8.40. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/kepler-capital-sticks-to-its-buy-rating-for-genfit-gnftf-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/kepler-capital-sticks-to-its-buy-rating-for-genfit-gnftf-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF"],"gpt_icon":0},{"id":"2507614578","title":"GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2507614578","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507614578?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 15:40","pubTimestamp":1738222800,"startTime":"0","endTime":"0","summary":"GENFIT signs royalty financing deal with HealthCare Royalty  providing up to 185 million non-dilutive capital:. 130 million upfront, with eligibility to receive up to 55 million in two additional instalments based on near-term milestones. Closing subject to approval by the 2025 OCEANE bondholders at upcoming bondholders meeting. Financing would extend cash runway beyond the end of 2027, assuming drawdown of all instalments. Proceeds to further strengthen the development of the ACLF pipeline. In return, HCRx will receive a portion of royalties on global1 sales of Iqirvo  payable to GENFIT under its licensing agreement with Ipsen, up to an agreed upon cap after which all future royalties will revert back to GENFIT. GENFIT retains rights to all future regulatory, commercial and sales-based milestone payments from Ipsen under the Ipsen agreement. GENFIT to concurrently propose a repurchase of the 2025 OCEANEs aiming to completely eliminate GENFIT’s convertible debt overhang","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genfit-announces-non-dilutive-royalty-074000804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBC","GNFT","BK4139","USA","GNFTF","CCA"],"gpt_icon":0},{"id":"2507665944","title":"GENFIT Announces 2025 Financial Calendar","url":"https://stock-news.laohu8.com/highlight/detail?id=2507665944","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507665944?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 05:10","pubTimestamp":1738185000,"startTime":"0","endTime":"0","summary":"Lille , Cambridge , Zurich , January 29, 2025 - GENFIT , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2025.Publication of revenue and cash position at December 31, 2024. Publication of Full Year 2024 financial statements  The 2024 Universal Registration Document and Annual Financial Report , as well as the Annual Report on Form 20-F will be made public by the end of April 2025.This press release contains certain forward-looking statements, including those w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genfit-announces-2025-financial-calendar-211000875.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GNFTF","GNFT","BK4139","USA","PBC","CCA"],"gpt_icon":0},{"id":"2503075555","title":"GENFIT Releases Half-Year Liquidity Contract Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2503075555","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503075555?lang=en_us&edition=full_marsco","pubTime":"2025-01-14 05:34","pubTimestamp":1736804070,"startTime":"0","endTime":"0","summary":"An update from Genfit SA ( ($GNFT) ) is now available. GENFIT announced the half-year report of its liquidity contract with Crédit Industriel et Co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genfit-releases-half-year-liquidity-contract-report?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genfit-releases-half-year-liquidity-contract-report?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNFTF","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genfit.com/","stockEarnings":[{"period":"1week","weight":-0.0739},{"period":"1month","weight":-0.1879},{"period":"3month","weight":-0.2811},{"period":"6month","weight":-0.4502},{"period":"1year","weight":-0.3426},{"period":"ytd","weight":-0.317}],"description":"Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.","exchange":"PINK LIMITED","name":"Genfit","nameEN":"Genfit"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.31.7","shortVersion":"4.31.7","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Genfit(GNFTF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Genfit(GNFTF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Genfit,GNFTF,Genfit股票,Genfit股票老虎,Genfit股票老虎国际,Genfit行情,Genfit股票行情,Genfit股价,Genfit股市,Genfit股票价格,Genfit股票交易,Genfit股票购买,Genfit股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Genfit(GNFTF),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Genfit(GNFTF) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}